Plazomicin(Cat No.:R057829)is a next-generation aminoglycoside antibiotic used to treat serious bacterial infections, particularly those caused by multidrug-resistant Gram-negative bacteria, including Escherichia coli and Klebsiella pneumoniae. It works by inhibiting bacterial protein synthesis, leading to bacterial cell death. Plazomicin is designed to overcome resistance mechanisms that affect older aminoglycosides, such as enzymatic degradation, making it effective against resistant strains. It is primarily used for complicated urinary tract infections and bloodstream infections, offering a potent option for treating infections where other antibiotics may fail due to resistance.
Catalog Number | R057829 |
CAS Number | 1154757-24-0 |
Synonyms | O-2-Amino-2,3,4,6-tetradeoxy-6-[(2-hydroxyethyl)amino]-α-D-glycero-hex-4-enopyranosyl-(1→4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-D-streptamine; ACHN 490; |
Molecular Formula | C25H48N6O10 |
Purity | 85% |
Target | MRM2 |
Target Protein | Q9UI43,,, |
Appearance | Solid |
Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
IUPAC Name | (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide |
InChI | InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1 |
InChIKey | IYDYFVUFSPQPPV-PEXOCOHZSA-N |
SMILES | C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CNCCO)N)N)NC(=O)[C@H](CCN)O)O |